Biomarkers /
GNAQ
Overview
GNAQ (guanine nucleotide binding protein [G protein], q polypeptide) is a gene that guanine nucleotide-binding protein G(q) subunit alpha, a subunit of one of the heterotrimeric guanine nucleotide binding proteins (G proteins). Oncogenic mutations result in a constitutively active Gα subunit (PMID: 1328859; PMID: 2549426). Receptor activation causes the dissociation of the Gα subunit from Gßγ. Both Gα and Gßγ can then activate downstream cellular signaling pathways (PMID: 1328859; PMID: 2549426).
GNAQ is altered in 0.69% of all cancers with uveal melanoma, lung adenocarcinoma, melanoma, endometrial endometrioid adenocarcinoma, and colon adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in GNAQ are GNAQ Mutation (0.61%), GNAQ Exon 5 Mutation (0.24%), GNAQ Codon 209 Missense (0.19%), GNAQ Q209P (0.12%), and GNAQ Q209L (0.07%) [3].
Clinical Trials
Significance of GNAQ in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.